Coluracetam Nootropic Review (Mild, Yet Pleasant)
Channel: RealJoshTv
Date: 24/06/2022

Hello Friends! Today I wanted to share my thoughts on Coluracetam, a member of the racetam family of nootropics. Have YOU tried Coluracetam?

https://buydmaaonline.com/product/buy-coluracetam-powder-99-9-pure/

Instagram - realjoshtv

BE SURE TO LIKE, COMMENT, SUBSCRIBE / CLICK THE NOTIFICATIONS BELL! so you don't miss out on any new videos!

Coluracetam (BCI-540, MKC-231) is a synthetic Nootropic drug in the racetam family that was initially developed by Mitsubishi Tanabe Pharma Corporation and later by Brain Cells Inc.

It was initially developed as a potential clinical therapy for Alzheimer’s Disease, but after trials failed to reach endpoints it was developed further for the treatment of major depressive disorder (MDD). Brain Cells Inc. reached phase 2a clinical trials which suggested that it may have potential as a medication for comorbid MDD and generalized anxiety disorder (GAD).

Animal studies have shown post-administration (10mg/kg) plasma concentrations of 4.289+/-0.641µg/mL (30 minutes), 0.717+/-0.350µg/mL (3 hours), and 0.037+/-0.010µg/mL (24 hours). After 14 days of use, there did not appear to be any effects on pharmacokinetics, indicating no tolerance build-up.

Like other racetam compounds, Coluracetam has AMPA potentiating activity. Unlike most other racetams, it was additionally designed to activate the cholinergic system. It is therefore of interest to researchers involved in studies regarding the choline transport system, protection against cognitive impairment, and neurochemical pathways for the development of novel antidepressants.

Coluracetam has cholinergic activity, significantly enhancing high-affinity choline uptake (HACU) – known to be the rate-limiting step of acetylcholine (ACh) synthesis. BCl-540 increases Vmax (1.6fold) of HACU as well as Bmax (1.7fold) of [3H]-HC-3 binding, with a strong affinity for high-affinity choline transporters (CHT1).

The enhancement of HACU velocity is of great importance to researchers in the fields of Alzheimer’s and other dementias. A variety of research has pointed to perturbation in HACU activity in Alzheimer’s patients. Preliminary evidence shows that the HACU activity-enhancing effects of BCl-540 may be limited to subjects with malfunctioning acetylcholine systems, without significant effects on otherwise healthy subjects.

In 1998, Akaike et al. published results indicating that Coluracetam has the potential to help protect the brain from glutamate neurotoxicity induced by ionomycin, through the suppression of NO synthesis triggered by increased Ca2+ influx. However, the study used a concentration higher than normal for the molecule (10µM), indicating that the results may not be practically relevant.